Medullary Thyroid Cancer Ppts and Recently published articles

Medullary Thyroid Cancer
by Travis Baggett
http://www.bcm.edu/sims/Files/vignette2.ppt

Surgical Treatment  of Medullary Carcinoma of the Thyroid 
by Jacques Peltier  MD, Francis B. Quinn,  MD
CA-thyroid-slides-070120.ppt

Pediatric  Thyroid Malignancies
by Kristen Boyle,  MD
ModificationDate=1264544885803

Evaluation of a Thyroid Nodule
by Michael E. Decherd, MD, Matthew W. Ryan, MD
http://med.mui.ac.ir/clinical/ent/Thyroid-Nodule-2002-01-slides.ppsx

Update in the Management of Thyroid Neoplasms
by David R. Byrd, MD
http://depts.washington.edu/surgstus/Clerkship/Lectures/print/Thyroid_Byrd.ppt

Medullary Thyroid Cancer
by David  M. Gleinser, MD, Susan  D. McCammon, MD
Thyroid-ca-slides-101027.ppt

Thyroid Cancer
by Christopher Muller
ThyroidCA-9810.ppt

Evaluation  of Thyroid Nodules
by Eric  Oliver
RadiologyThyroid.ppt

Evaluation of the Effects of Low Dose Radiation-dose reconstruction
by Lynn  R. Anspaugh, Ph.D
Anspaugh-Radiation_Dose_Reconstruction.ppt

Evaluation of Thyroid Nodules
by Michael L. Tuggy, MD
Thyroid nodules.ppt

Pathology of the Thyroid Gland
by Prof. Dipak Shah
Thyroiddiseases.ppt


Recently Published articles

1. Response to "Single nucleotide polymorphisms and development of hereditary medullary thyroid cancer in V804M RET families: Disease modification or linkage disequilibrium?"
2. Medullary thyroid cancer and pseudocirrhosis: case report and literature review.
3. Celecoxib, a cyclooxygenase-2 inhibitor, potentiates the chemotherapic effect of vinorelbine in the medullary thyroid cancer TT cell line.
4. Dens of Axis Metastasis from Medullary Thyroid Cancer.
5. Clinical utility of vandetanib in the treatment of patients with advanced medullary thyroid cancer.
6. Vandetanib (Caprelsa) for medullary thyroid cancer.
7. LOW PREVALENCE OF THE SOMATIC M918T RET MUTATION IN MICRO-MEDULLARY THYROID CANCER.
8. Comparison of Calcium and Pentagastrin Tests for the Diagnosis and Follow-Up of Medullary Thyroid Cancer.
9. Unusual adverse event with vandetanib in metastatic medullary thyroid cancer.
10. Completing the Arc: targeted inhibition of RET in medullary thyroid cancer.
11. RET mutations and medullary thyroid cancer.
12. Clinical Relevance of RET Variants G691S, L769L, S836S and S904S to Sporadic Medullary Thyroid Cancer.
13. Pharmacotherapy: vandetanib-a new therapeutic option in advanced medullary thyroid cancer.
14. Complementary roles of 18F-DOPA PET/CT and 18F-FDG PET/CT in medullary thyroid cancer.
15. Prognostic value of clinical, histological and immunohistochemical features in medullary thyroid cancer.
16. Progress in molecular targeted therapy for thyroid cancer: vandetanib in medullary thyroid cancer.
17. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
18. MiR-886-3p regulates cell proliferation and migration, and is dysregulated in familial non-medullary thyroid cancer.
19. Anti-proliferative effect and action mechanism of dexamethasone in human medullary thyroid cancer cell line.
20. Surgical management of sporadic medullary thyroid cancer.
21. Everolimus is an active agent in medullary thyroid cancer: a clinical and in vitro study.
22. Single nucleotide polymorphisms and development of hereditary medullary thyroid cancer in V804M RET families: Disease modification or linkage disequilibrium?
23. Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer.
24. Allelic loss of susceptibility loci and the occurrence of BRAF and RAS mutations in patients with familial non-medullary thyroid cancer.
25. Targeted treatment of differentiated and medullary thyroid cancer.
26. Evaluation of efficacy and clinical impact of (18)F-FDG-PET in the diagnosis of recurrent medullary thyroid cancer with increased calcitonin and negative imaging test.
27. In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer.
28. Targeted systemic radiotherapy of pheochromocytoma and medullary thyroid cancer.
29. Current role of metaiodobenzylguanidine in the diagnosis of pheochromocytoma and medullary thyroid cancer.
30. How to Treat a Signal? Current Basis for RET-Genotype-Oriented Choice of Kinase Inhibitors for the Treatment of Medullary Thyroid Cancer.
31. Metastatic medullary thyroid cancer presenting with elevated levels of CA 19-9 and CA 125.
32. Interplay between Ret and Fap-1 regulates CD95-mediated apoptosis in medullary thyroid cancer cells.
33. Germline RET sequence variation I852M and occult medullary thyroid cancer: harmless polymorphism or causative mutation?
34. Updates in the management of medullary thyroid cancer.
35. Patients with familial non-medullary thyroid cancer have an outcome similar to that of patients with sporadic papillary thyroid tumors.
36. Expression of hypoxia-associated proteins in sporadic medullary thyroid cancer is associated with desmoplastic stroma reaction and lymph node metastasis and may indicate somatic mutations in the VHL gene.
37. MicroRNA profiling of sporadic and hereditary medullary thyroid cancer identifies predictors of nodal metastasis, prognosis, and potential therapeutic targets.
38. Response to "Long-term outcome of 'prophylactic therapy' for familial medullary thyroid cancer (MTC)".
39. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
40. Measuring calcitonin in washout of the needle in patients undergoing fine needle aspiration with suspicious medullary thyroid cancer.
41. Medullary Thyroid Cancer: It is a pain in the neck?
42. Ultrasonographic findings of medullary thyroid cancer: differences according to tumor size and correlation with fine needle aspiration results.
43. Medullary thyroid cancer: clinico-pathological profile and outcome in a tertiary care center in North India.
44. Management of medullary thyroid cancer.
45. Detection by SPECT-CT scan with (99m)Tc-(V) DMSA of bone metastases in patient with medullary thyroid cancer.
46. Pediatric ethics guidelines for hereditary medullary thyroid cancer.
47. Antitumor Activity of Motesanib in a Medullary Thyroid Cancer Model.
48. Clinical review: Incidentally discovered medullary thyroid cancer: diagnostic strategies and treatment.
49. Positron emission tomography in non-medullary thyroid cancer.
50. Cancer: RET screening uncovers hidden cases of hereditary medullary thyroid cancer.